Genetic variability and potential effects on clinical trial outcomes: perspectives in Parkinson’s disease
- 29 November 2019
- journal article
- research article
- Published by BMJ in Journal of Medical Genetics
- Vol. 57 (5), 331-338
- https://doi.org/10.1136/jmedgenet-2019-106283
Abstract
Background Classical randomisation of clinical trial patients creates a source of genetic variance that may be contributing to the high failure rate seen in neurodegenerative disease trials. Our objective was to quantify genetic difference between randomised trial arms and determine how imbalance can affect trial outcomes. Methods 5851 patients with Parkinson’s disease of European ancestry data and two simulated virtual cohorts based on public data were used. Data were resampled at different sizes for 1000 iterations and randomly assigned to the two arms of a simulated trial. False-negative and false-positive rates were estimated using simulated clinical trials, and per cent difference in genetic risk score (GRS) and allele frequency was calculated to quantify variance between arms. Results 5851 patients with Parkinson’s disease (mean (SD) age, 61.02 (12.61) years; 2095 women (35.81%)) as well as simulated patients from virtually created cohorts were used in the study. Approximately 90% of the iterations had at least one statistically significant difference in individual risk SNPs between each trial arm. Approximately 5%–6% of iterations had a statistically significant difference between trial arms in mean GRS. For significant iterations, the average per cent difference for mean GRS between trial arms was 130.87%, 95% CI 120.89 to 140.85 (n=200). Glucocerebrocidase (GBA) gene-only simulations see an average 18.86%, 95% CI 18.01 to 19.71 difference in GRS scores between trial arms (n=50). When adding a drug effect of −0.5 points in MDS-UPDRS per year at n=50, 33.9% of trials resulted in false negatives. Conclusions Our data support the hypothesis that within genetically unmatched clinical trials, genetic heterogeneity could confound true therapeutic effects as expected. Clinical trials should undergo pretrial genetic adjustment or, at the minimum, post-trial adjustment and analysis for failed trials.Keywords
This publication has 31 references indexed in Scilit:
- Heterogeneity of Leucine-Rich Repeat Kinase 2 Mutations: Genetics, Mechanisms and Therapeutic ImplicationsNeurotherapeutics, 2014
- Large-scale meta-analysis of genome-wide association data identifies six new risk loci for Parkinson's diseaseNature Genetics, 2014
- Alzheimer’s disease drug-development pipeline: few candidates, frequent failuresAlzheimer's Research & Therapy, 2014
- The glucocerobrosidase E326K variant predisposes to Parkinson's disease, but does not cause Gaucher's diseaseMovement Disorders, 2013
- The link between the GBA gene and parkinsonismThe Lancet Neurology, 2012
- Calibration of unified Parkinson's disease rating scale scores to Movement Disorder Society‐unified Parkinson's disease rating scale scoresMovement Disorders, 2012
- ApoE genotyping as a progression-rate biomarker in phase II disease-modification trials for Alzheimer's diseaseThe Pharmacogenomics Journal, 2009
- Illustrating bias due to conditioning on a colliderInternational Journal of Epidemiology, 2009
- The NCBI dbGaP database of genotypes and phenotypesNature Genetics, 2007
- Effect of age at onset on progression and mortality in Parkinson's diseaseNeurology, 1989